Halozyme Therapeutics Inc. has announced a global collaboration and exclusive license agreement with Takeda to develop and commercialize vedolizumab with Halozyme’s ENHANZE® drug delivery technology. The agreement grants Takeda exclusive access to the ENHANZE® platform, which utilizes the proprietary recombinant human hyaluronidase PH20 enzyme, for use with vedolizumab, marketed as ENTYVIO. Under the terms of the deal, Takeda will make an upfront payment to Halozyme, with additional potential development and commercial milestone payments, as well as royalties on sales of vedolizumab products utilizing ENHANZE®. This partnership aims to enhance treatment flexibility and patient experience for those living with ulcerative colitis and Crohn’s disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58811) on January 08, 2026, and is solely responsible for the information contained therein.